The US FDA may be plunged into the middle of a new fight over the future of the Affordable Care Act, as its biosimilar approval pathway is potentially at risk.
Indeed, among the many provisions in the ACA was creation of an abbreviated approval mechanism for biosimilars, which
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?